• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

The NAMSAL ANRS 12313 trial: HIV viral suppression similar for dolutegravir and low-dose efavirenz treatment

byDayton McMillan
September 6, 2019
in Chronic Disease, Infectious Disease, Obstetrics, Public Health
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. For previously untreated HIV-1 patients in Cameroon, treatment with dolutegravir was noninferior to low dose efavirenz at lowering viral load over a period of 48 weeks.

2. Weight gain occurred in both groups but was more evident in the dolutegravir treated patients.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: For many years the World Health Organization recommended initial human immunodeficiency virus type 1 (HIV-1) antiretroviral therapy to consist of the non-nucleoside reverse-transcriptase inhibitor efavirenz 600mg, as part of a combination of three anti-retroviral drugs. Recent studies have suggested the integrase inhibitor dolutegravir may be an ideal first-line HIV therapy due to its efficacy, high barrier to resistance, low production costs, and the newly considered neurodevelopmental risks of efavirenz. To evaluate efficacy and safety of possible HIV therapies in a resource limited context, the phase 3 New Antiretroviral and Monitoring Strategies in HIV-Infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 study compared low-dose efavirenz 400mg (EFV400), which had previously been shown to be noninferior to efavirenz 600mg,  to dolutegravir. The primary endpoint, the proportion of patients with a viral load of less than 50 copies/mL at 48 weeks, showed that dolutegravir was noninferior to EFV400. Virologic failure, having more than 1000 copies/mL, occurred in more EFV400 patients. Weight gain was notable in dolutegravir treated patients.

This study evaluates contested HIV treatment options in a resource limited country of Cameroon, providing more generalizable results than other similar studies conducted in different settings. A strength of the study is the extensive subgroup analysis while it is limited by its length of follow-up only out to 48 weeks and patients were only enrolled at hospitals in an urban setting.

Click to read the study in the NEJM (New England Journal of Medicine)

RELATED REPORTS

Weekly islatravir plus lenacapavir maintains HIV virologic suppression

Ending Ryan White services may increase human immunodeficiency virus incidence

Relevant Reading: Dolutegravir for the treatment of HIV

FDA approvedFor HIV: Idvynso (doravirine and islatravir), Apr 20, 2026→

In-Depth [randomized controlled trial]: This phase 3, open-label, randomized controlled trial enrolled Cameroonian patients between 2016 and 2017. Eligible patients were adults with HIV-1 group m infection who had not yet received antiretroviral therapy. Use of contraceptive methods was required for women of childbearing age. Patients with severe liver, renal, psychiatric, or tuberculosis disease were excluded.  Patients were stratified during randomization by viral load and trial site, and assigned to a dolutegravir (n=292) or EFV400 (n=297) group. Analysis was performed on a per-protocol basis. The primary outcome, viral load of less than 50 copies/mL at week 48, occurred in 74.5% and 69.0% of dolutegravir and EFV400 patients, respectfully (difference of 5.5%, (95% confidence interval [CI], −1.6% to 12.7%), indicating noninferiority of dolutegravir but not superiority. For patients with a baseline viral load of greater than 100,000 copies/mL, 66.2% and 61.5% of dolutegravir and EFV400 patients had a viral load of less than 50 copies/mL at week 48 (4.7% difference; 95% CI, −4.6 to 14.0) showing dolutegravir noninferiority. When viral suppression was defined as less than 200 copies/mL at week 48 dolutegravir was both noninferior and superior compared to EFV400. In multiple subgroup analyses for efficacy dolutegravir trended towards showing superiority in viral load suppression. Of the women on trial drugs who became pregnant during the study, 13 and 12 on dolutegravir and EFV400, respectively, none had children born with congenital abnormalities. Median weight gain was greater in dolutegravir (5.0kg) compared to EFV400 (3.0kg) treated patients (P<0.001).

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: CameroonDolutegravirefavirenzhuman immunodeficiency virus (HIV)
Previous Post

Quick Take: Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis

Next Post

The RELAX-AHF-2 trial: serelaxin provides no mortality benefit in acute heart failure patients

RelatedReports

HIV care collage: a smiling middle-aged man with an awareness ribbon pinned to his shirt beside a sprig of olive leaves
Chronic Disease

Weekly islatravir plus lenacapavir maintains HIV virologic suppression

December 22, 2025
Institute of Medicine identifies cost variation between geographic regions
Infectious Disease

Ending Ryan White services may increase human immunodeficiency virus incidence

September 8, 2025
HIV care collage: an engraved immune cell inside a ring of torn blue paper, with a small teal shield and a teal ribbon
Infectious Disease

Anal cancer screening cost-effective for men who have sex with men with human immunodeficiency virus aged above 35 years

June 16, 2025
Combined immunotherapy may improve survival in metastatic pancreatic cancer
Infectious Disease

Safety of investigational vaccines against human immunodeficiency virus

April 29, 2025
Next Post

The RELAX-AHF-2 trial: serelaxin provides no mortality benefit in acute heart failure patients

#VisualAbstract: An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

#VisualAbstract: An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

#VisualAbstract: Liraglutide in Children and Adolescents with Type 2 Diabetes

#VisualAbstract: Liraglutide in Children and Adolescents with Type 2 Diabetes

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Medicaid-reimbursed weight-loss GLP-1 prescriptions fell after coverage withdrawal in 4 states
  • Social isolation and loneliness is associated with worse physical and mental health among middle-aged and older adults
  • Gait analysis predicts health, sleep, and medication use across 18 body systems
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.